MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...
Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Subcutaneous (SC) administration of medication and fluids for end-of-life cancer care is underutilized in the United States, despite this route having advantages over intravenous (IV) administration, ...
Implementing routine electronic patient-reported health literacy screening for new adult oncology patients to improve patient care at the individual and population level.
The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback